Drug Profile
Research programme: niacin receptor agonists - Pfizer/Merck & Co
Latest Information Update: 16 Mar 2022
Price :
$50
*
At a glance
- Originator Arena Pharmaceuticals
- Developer Arena Pharmaceuticals; Merck & Co
- Class Anthranilic acids; Small molecules
- Mechanism of Action G protein-coupled receptor agonists; GPR109A receptor agonists; GPR109B receptor agonists; Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 24 Dec 2009 Discontinued - Preclinical for Atherosclerosis in USA (PO)
- 20 Aug 2009 Pharmacodynamics data from a Preclinical trial in Atherosclerosis presented at the 238th American Chemical Society National Meeting (238th-ACS-2009)